Loading organizations...
§ Private Profile · 100 Edwin H Land Blvd, Cambridge, Massachusetts, 02142, United States
Solarea Bio is a technology company.
Solarea Bio develops microbiome-based solutions for human health, primarily addressing age-related conditions. The company employs its proprietary Microscape Technology™ to isolate beneficial bacteria and fungi found in fruits and vegetables. These natural microbes are formulated into therapeutic medical foods designed to modulate inflammatory processes, enhancing well-being.
Founded in 2017 by Gerardo V. Toledo and Eric Schott, Solarea Bio emerged from a collective insight into the significant, often untapped, potential of the human microbiome to influence health and aging. This fundamental understanding fueled their ambition to innovate traditional wellness approaches by leveraging plant-derived microbial communities.
The company's offerings are designed for individuals proactive in managing age-related health concerns, with an emphasis on areas like bone health. Solarea Bio's mission is to advance the future of aging by measurably improving health outcomes. It strives to enable people to lead longer, healthier lives through science-backed, natural solutions.
Solarea Bio has raised $26.0M across 2 funding rounds.
Solarea Bio has raised $26.0M in total across 2 funding rounds.
Solarea Bio has raised $26.0M in total across 2 funding rounds.
Solarea Bio's investors include Matthew Walker, Bold Capital Partners, Social Starts, GG 1978 SICAF SIF, Viking Global Investors, GISEV.
Solarea Bio has raised $26.0M across 2 funding rounds. Most recently, it raised $15.0M Series B in May 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2023 | $15M Series B | Matthew Walker | Bold Capital Partners, Social Starts, GG 1978 Sicaf SIF, Viking Global Investors | Announced |
| Oct 1, 2020 | $11M Series A | Bold Capital Partners, Matthew Walker | Social Starts, Gisev, Viking Global Investors | Announced |
Solarea Bio is a clinical-stage biotechnology company headquartered in Cambridge and Waltham, Massachusetts, developing "food as medicine" solutions by mining microbes from fresh fruits and vegetables to treat inflammatory disorders, age-related conditions like postmenopausal bone loss, and support overall health.[1][2][3] The company builds a proprietary microbial library of over 5,000 isolates (with 16 million genes and 7 million biosynthetic clusters), powered by Microscape Technology—an AI-driven platform for isolating, sequencing, and commercializing strains into products like dietary supplements, therapeutic foods (e.g., Journa™ brand's Bondia™ synbiotic for osteopenia), pharmaceuticals, and agricultural probiotics.[1][2] It serves consumers, patients with autoimmune diseases or bone loss, healthcare practitioners, and food/agriculture industries, addressing unmet needs in gut health, musculoskeletal inflammation, and aging by leveraging natural, probiotic microbes overlooked in traditional sources.[1][2]
Growth momentum includes a 2021 tech licensing deal with ADM for food/beverage applications, participation in Illumina Accelerator, patent filings for microbial seed coatings, launch of consumer brand Journa™ in 2025 with early access to Bondia™ ahead of full fall rollout post-clinical trial data, and a $15M Series B first close led by S2G Ventures.[1][2][4]
Solarea Bio emerged from the co-founders' discovery of untapped probiotic bacteria and fungi in fresh fruits and vegetables, linking them to anti-inflammatory benefits like the gut-musculoskeletal axis.[1] CEO and co-founder Dr. Gerardo V. Toledo, alongside collaborators, built this insight into a platform starting with a discovery campaign at the Illumina Accelerator, involving gut-relevant isolation, genome-wide metabolic predictions, and validation via metabolomics.[1] Key early traction came from the 2021 ADM licensing agreement, validating their microbial platform for health-focused food formulations, and subsequent patent applications for single strains and defined microbial assemblies (DMAs) in agriculture.[1] The company evolved from biotech R&D in Cambridge to clinical-stage operations, culminating in 2025 consumer launches under Journa™ and Series B funding.[1][2][4]
Solarea Bio rides the food-as-medicine and microbiome therapeutics waves, capitalizing on rising demand for natural, anti-inflammatory solutions amid aging populations and chronic conditions like osteoporosis (affecting women disproportionately) and autoimmune diseases.[2][3] Timing aligns with post-2020 biotech surges in precision nutrition, AI-driven discovery, and synbiotics, amplified by wellness trends favoring fruits/veg-derived microbes over synthetic alternatives.[1][2] Market forces include regulatory nods for medical foods, investor interest (e.g., $15M Series B), and partnerships like ADM, positioning Solarea to disrupt $50B+ probiotics/supplements and $100B+ ag-bio markets while influencing ecosystems via open platforms for strain sharing and crop resilience.[1][4]
Solarea Bio's trajectory points to Bondia™'s full 2025 launch post-trial data, pipeline expansion into more age-related therapies via Microscape, and potential Series B completion for scaling manufacturing/partnerships.[2][4] Trends like AI-biotech convergence, personalized aging nutrition, and sustainable ag-probiotics will propel growth, evolving its influence from niche innovator to ecosystem shaper in natural microbiome solutions. As a pioneer unlocking food's microbial goldmine, Solarea exemplifies biotech's shift toward preventive, nature-sourced health.